These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 31325141)

  • 1. What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.
    Sumi CD; Heffernan AJ; Lipman J; Roberts JA; Sime FB
    Clin Pharmacokinet; 2019 Nov; 58(11):1407-1443. PubMed ID: 31325141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.
    Abdelraouf K; Linder KE; Nailor MD; Nicolau DP
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):705-714. PubMed ID: 28486001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualising Therapy to Minimize Bacterial Multidrug Resistance.
    Heffernan AJ; Sime FB; Lipman J; Roberts JA
    Drugs; 2018 Apr; 78(6):621-641. PubMed ID: 29569104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance.
    Xu L; Wang H; Yang X; Lu L
    BMC Vet Res; 2013 Jun; 9():126. PubMed ID: 23800340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically?
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Chemother; 2017 Dec; 29(6):351-357. PubMed ID: 28587559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria.
    Luna BM; Ershova K; Yan J; Ulhaq A; Nielsen TB; Hsieh S; Pantapalangkoor P; Vanscoy B; Ambrose P; Rudin S; Hujer K; Bonomo RA; Actis L; Skaar EP; Spellberg B
    J Antimicrob Chemother; 2019 Sep; 74(9):2631-2639. PubMed ID: 31170282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
    Boothe DM; Boeckh A; Simpson RB; Dubose K
    J Vet Intern Med; 2006; 20(6):1297-306. PubMed ID: 17186841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.
    Furtado GH; Cardinal L; Macedo RS; Silva JO; Medeiros EA; Kuti JL; Nicolau DP
    Rev Soc Bras Med Trop; 2015; 48(5):539-45. PubMed ID: 26516962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.
    Labreche MJ; Frei CR
    Am J Health Syst Pharm; 2012 Nov; 69(21):1863-70. PubMed ID: 23111670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.
    Firsov AA; Strukova EN; Shlykova DS; Portnoy YA; Kozyreva VK; Edelstein MV; Dovzhenko SA; Kobrin MB; Zinner SH
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4956-62. PubMed ID: 23896481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.
    Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH; Firsov AA
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1208-15. PubMed ID: 26643328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice.
    Wicha SG; Mundkowski RG; Klock A; Hopt UT; Drewelow B; Kloft C; Wellner UF; Keck T; Wittel UA
    J Clin Pharmacol; 2019 Oct; 59(10):1405-1414. PubMed ID: 31111505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.